Grant: Discovery Grants Program - Individual
McGill University
$24,000.00
Novel organosilicon molecular scaffolds as a platform to design positron emission tomography tracers via Si-18F bond formation (SiFEx).
EF 2022-23
Résumé
I will develop novel organosilicon scaffolds amenable for facile radiolabeling with an isotope fluorine-18 to design the new generation of imaging agents for positron emission tomography (PET). PET is an in vivo imaging modality which relies on the detection of radioactive decay of isotopes embedded within biologically active molecules, called tracers, administered to a patient or study subject. Fluorine-18 is the most widely used PET isotope due to its ideal nuclear properties. However, its late-stage incorporation into certain classes of biologically relevant compounds, especially macromolecules and fragile small molecules, remains challenging due to the harsh reaction conditions required for C-18F bond formation. This often impedes development of new PET tracers, their implementation in manufacturing settings and translation to the clinic. The fluorine isotope exchange reaction on silicon (Si-19F for Si-18F), hereafter termed SiFEx, offers a high-yielding, operationally simple and robust method for the incorporation of radioactive 18F into PET tracer candidates. The class of fluorosilane scaffolds amenable for this radiolabeling technique was coined silicon fluoride acceptors (SiFA). Despite significant recent advances, the large carbon footprint of the phenyl and two tert-butyl substituents on silicon results in unfavorable pharmacokinetic properties of the current generation of SiFA scaffolds. This drawback has limited their applications to radiolabeling larger macromolecules, such as peptides and proteins, and precluded the development of small silicon-containing molecule PET tracers. The latter would be especially advantageous for the design of tracers for brain PET imaging. My program aims to improve pharmacokinetic properties of SiFA molecules with a primary goal of designing new generation of silicon-containing 18F-labeled PET tracers. We will first seek to substitute the phenyl with heteroaromatic rings that represent common motifs in medicinal chemistry. Next, we will investigate the remote substituent effect on the heteroaromatic ring on stability of Si-F and C-Si bonds via electronic and steric factors. We will then reduce the size of the substituents on the silicon by replacing the bulky tert-butyls with smaller alkyl groups and incorporate silicon into compact druglike 6- or 8-membered silacycle scaffolds. My program will address the key limitations of the current SiFA technology and lead to development of druglike organosilicon compounds towards rational design of novel PET tracers. A new generation of [18F]fluorosilane scaffolds will combine the unprecedented radiolabeling efficiency and reproducibility of SiFA technology with the possibility to tune key pharmacokinetic properties of PET tracers with potential exciting applications in brain imaging. My program will also expand the role of silicon in medicinal chemistry and develop new synthetic methods for its incorporation into molecular scaffolds suitable for drug design.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2022-04300
Name nom
Kostikov, Alexey
Department département
Neurology and Neurosurgery - Neurology and Neurosurgery
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2022
Award amount
24000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Installment
inst:1
Partie
1
Nb partie
5
Application title
Novel organosilicon molecular scaffolds as a platform to design positron emission tomography tracers via Si-18F bond formation (SiFEx).
Application summary
I will develop novel organosilicon scaffolds amenable for facile radiolabeling with an isotope fluorine-18 to design the new generation of imaging agents for positron emission tomography (PET). PET is an in vivo imaging modality which relies on the detection of radioactive decay of isotopes embedded within biologically active molecules, called tracers, administered to a patient or study subject. Fluorine-18 is the most widely used PET isotope due to its ideal nuclear properties. However, its late-stage incorporation into certain classes of biologically relevant compounds, especially macromolecules and fragile small molecules, remains challenging due to the harsh reaction conditions required for C-18F bond formation. This often impedes development of new PET tracers, their implementation in manufacturing settings and translation to the clinic. The fluorine isotope exchange reaction on silicon (Si-19F for Si-18F), hereafter termed SiFEx, offers a high-yielding, operationally simple and robust method for the incorporation of radioactive 18F into PET tracer candidates. The class of fluorosilane scaffolds amenable for this radiolabeling technique was coined silicon fluoride acceptors (SiFA). Despite significant recent advances, the large carbon footprint of the phenyl and two tert-butyl substituents on silicon results in unfavorable pharmacokinetic properties of the current generation of SiFA scaffolds. This drawback has limited their applications to radiolabeling larger macromolecules, such as peptides and proteins, and precluded the development of small silicon-containing molecule PET tracers. The latter would be especially advantageous for the design of tracers for brain PET imaging. My program aims to improve pharmacokinetic properties of SiFA molecules with a primary goal of designing new generation of silicon-containing 18F-labeled PET tracers. We will first seek to substitute the phenyl with heteroaromatic rings that represent common motifs in medicinal chemistry. Next, we will investigate the remote substituent effect on the heteroaromatic ring on stability of Si-F and C-Si bonds via electronic and steric factors. We will then reduce the size of the substituents on the silicon by replacing the bulky tert-butyls with smaller alkyl groups and incorporate silicon into compact druglike 6- or 8-membered silacycle scaffolds. My program will address the key limitations of the current SiFA technology and lead to development of druglike organosilicon compounds towards rational design of novel PET tracers. A new generation of [18F]fluorosilane scaffolds will combine the unprecedented radiolabeling efficiency and reproducibility of SiFA technology with the possibility to tune key pharmacokinetic properties of PET tracers with potential exciting applications in brain imaging. My program will also expand the role of silicon in medicinal chemistry and develop new synthetic methods for its incorporation into molecular scaffolds suitable for drug design.